<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (LA) are associated with an increased risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> and laboratory detection is of major importance </plain></SENT>
<SENT sid="1" pm="."><plain>Multiple tests are available for screening and confirmation, but they differ in sensitivity and specificity, frequently lacking the ability to discriminate between the presence of LA, <z:chebi fb="5" ids="28304">heparin</z:chebi>, and oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Based on the test-principle of the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> Ratio-test, an automated, sensitive APTT-based assay, using mixtures of a lupussensitive and a lupusinsensitive APTT-reagent with <z:mpath ids='MPATH_458'>normal</z:mpath> plasma for detection of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> was developed </plain></SENT>
<SENT sid="3" pm="."><plain>Ninety-nine healthy volunteers, ten patients treated with unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> intravenously, 19 patients taking stable oral anticoagulation, five patients with <z:e sem="disease" ids="C0684275,C0019069" disease_type="Disease or Syndrome" abbrv="">hemophilia</z:e> A, and 15 patients with <z:hpo ids='HP_0003613'>antiphospholipid-antibody</z:hpo>-syndrome (APS) were investigated </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients, two APTTs were performed, one with each reagent, on 1:1 mixtures of test plasma and <z:mpath ids='MPATH_458'>normal</z:mpath> plasma (MIXCON-LA assay) </plain></SENT>
<SENT sid="5" pm="."><plain>The ratio between the two clotting times was divided by the corresponding ratio for the <z:mpath ids='MPATH_458'>normal</z:mpath> plasma </plain></SENT>
<SENT sid="6" pm="."><plain>This final <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> ratio (LR) was used for evaluation </plain></SENT>
<SENT sid="7" pm="."><plain>The within-series imprecision and the between-series imprecision were excellent with coefficients of variation between 1.5% and 1.9% </plain></SENT>
<SENT sid="8" pm="."><plain>The mean +/- 2 SD of the LR of the 99 healthy volunteers was used as reference range (LR: 0.95-1.07) </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients treated either with <z:chebi fb="5" ids="28304">heparin</z:chebi> or oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> remained negative in the MLXCON-LA assay (specificity, 100%), while one of five patients with <z:e sem="disease" ids="C0684275,C0019069" disease_type="Disease or Syndrome" abbrv="">hemophilia</z:e> A, in whom a factor VIII-inhibitor developed, showed a false-positive result </plain></SENT>
<SENT sid="10" pm="."><plain>In 13 of 15 patients with APS, an increased ratio was observed (sensitivity, 87%) </plain></SENT>
<SENT sid="11" pm="."><plain>This assay system allows precise, specific, and sensitive detection of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
</text></document>